Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

21. Aripiprazole

Aripiprazole USE OF ARIPIPRAZOLE IN PREGNANCY 0344 892 0909 USE OF ARIPIPRAZOLE IN PREGNANCY (Date of issue: March 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Aripiprazole is an atypical antipsychotic used (...) in the treatment of schizophrenia, manic episodes, bipolar disorder, and other psychoses. There are only two small cohort studies which specifically investigate the use of aripiprazole in pregnancy. Although aripiprazole exposures are included in a number of other studies which report on fetal outcome of women exposed to various antipsychotics, aripiprazole exposures generally represent only a small proportion of the study cohort and were not analysed separately. Human pregnancy data for aripiprazole are thus

UK Teratology Information Service2014

23. Aripiprazole (Abilify) - moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older

Aripiprazole (Abilify) - moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older

Scottish Medicines Consortium2013

24. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Moteshafi H, Stip E CRD summary The authors concluded (...) of schizophrenia and affective disorders. Searching PubMed, EMBASE and PsycINFO were searched up to 2010 without language restrictions. Search terms were reported. ClinicalTrials.gov was searched. Reference lists of relevant articles were checked for further studies. Study selection Eligible studies were randomised controlled trials (RCTs) that compared side effects of four antipsychotics (quetiapine, risperidone, ziprasidone and aripiprazole) in the treatment of patients (aged 18 to 65 years

DARE.2013

25. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292) Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | Guidance and guidelines | NICE Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder Technology appraisal guidance [TA292] Published date: 24 July 2013 Share Guidance wherever possible. Explore Guidance app Copyright © 2017 National Institute

National Institute for Health and Clinical Excellence - Technology Appraisals2013

27. Abilify maintena (aripiprazole) Extended-Release Injectable Suspension

Abilify maintena (aripiprazole) Extended-Release Injectable Suspension Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - ABILIFY MAINTENA (aripiprazole) Extended-Release Injectable Suspension Company: Otsuka Pharmaceutical Application No.: 202971 Approval Date: 02/28/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2013

28. Aripiprazole effective for schizophrenia and well tolerated

Aripiprazole effective for schizophrenia and well tolerated PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Aripiprazole effective for schizophrenia and well tolerated Clinical question How effective is aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses? Bottom line On the basis of very limited data, aripiprazole (...) was not as effective (in terms of general mental state) as olanzapine but was as effective as risperidone. Aripiprazole was associated with less weight gain, cholesterol increase and sedation, and fewer prolactinrelated effects than olanzapine. Compared to risperidone, aripiprazole produced fewer dystonias, cardiac arrhythmias, and prolactin and cholesterol increases. However, tremor was more frequent in the aripiprazole group compared to those allocated risperidone. Caveat The overall premature discontinuation

Cochrane PEARLS2011

30. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Kasteng F, Eriksson J, Sennfalt K, Lindgren P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of aripiprazole versus olanzapine for schizophrenia or bipolar disorder, focusing on the risk of developing treatment-related metabolic syndrome, leading to type 2 diabetes or coronary heart disease. The lower risk of metabolic syndrome

NHS Economic Evaluation Database.2011

31. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | Guidance and guidelines | NICE Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance [TA213] Published date: 26 January 2011 Share Guidance wherever possible. Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2011

32. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study

Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study King D, Knapp M, Thomas P, Razzouk D, Loze JY, Kan HJ, van Baardewijk (...) M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study aim was to compare the cost-effectiveness of aripiprazole with that of other atypical antipsychotic medicines for people with schizophrenia in the UK. The authors concluded

NHS Economic Evaluation Database.2011

35. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model

The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model Leelahanaj T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adding aripiprazole to conventional antidepressant treatment for patients with major depressive disorder who had not completely responded to at least one antidepressant. The author concluded that the addition of aripiprazole was not cost-effective in Thailand. The study was well presented

NHS Economic Evaluation Database.2010

36. Review: Is aripiprazole as effective as risperidone in people with schizophrenia?

Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Review: Is aripiprazole as effective as risperidone in people with schizophrenia? | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Article Text Therapeutics Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Statistics from Altmetric.com No Altmetric data available for this article. Question Question: What are the effects of aripiprazole compared

Evidence-Based Mental Health2010

38. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis Fountoulakis KN, Gonda X, Vieta E, Schmidt F CRD summary The authors concluded that aripiprazole was useful for the treatment of psychotic symptoms during the acute manic/mixed and maintenance phases (...) of bipolar illness. Given the high drop-out rates from trials, uncertainty over the quality of the included trials and potential for bias in the review, the authors’ conclusions should be interpreted with caution. Authors' objectives To assess the effectiveness of aripiprazole in the treatment of psychotic symptoms in patients with bipolar disorder. Searching MEDLINE was searched for relevant articles. Search terms were reported. Various other Internet sources were also searched, including Google

DARE.2009

39. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials

Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J CRD summary This review concluded that aripiprazole was effective in treating both depression and manic phase of bipolar disorder, but had relevant (...) side effects. A lack of details on trial quality and several methodological concerns in the review methods mean that the authors' conclusions may be not reliable. Authors' objectives To assess the efficacy of aripiprazole in the treatment of major depression and manic phase of bipolar disorder. Searching MEDLINE was searched up to April 2009. Search terms were reported. Reference lists of relevant publications were screened. The US National Institutes of Health Web page was also searched. Study

DARE.2009

40. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study)

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) Barnett A H, Millar H L, Loze J Y, L'Italien G J, van Baardewijk M, Knapp M Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the clinical effects and their associated costs for the treatment of patients with schizophrenia using aripiprazole compared with other typical antipsychotic medications. The authors concluded

NHS Economic Evaluation Database.2009